THE PURE CRAFT JOURNAL

CBD Gummies for Exercise Recovery and Athletic Performance: What Research Shows | PureCraft CBD

October 21, 2026

By PureCraft Editorial Team | PureCraft CBD | Updated October 2026

Exercise recovery — the cascade of cellular repair, protein synthesis, glycogen resynthesis, and neuroendocrine restoration that follows training — is arguably where athletic performance is actually built: the adaptation stimulus occurs during training, but the adaptation itself occurs during recovery. The endocannabinoid system (ECS) is deeply embedded in the biology of exercise and recovery: exercise itself produces a surge of endocannabinoids (the mechanism underlying the neurobiological component of "runner's high"); ECS receptors are expressed on satellite cells (the muscle stem cells that mediate muscle repair); CB2 receptors modulate the macrophage-driven inflammatory cascade of delayed onset muscle soreness (DOMS); AEA (anandamide) — elevated by FAAH inhibition — is now recognized as a primary endogenous mediator of exercise-induced neurological reward and mood; and the ECS interacts directly with the cortisol/mTORC1/protein synthesis axis that determines whether a training stimulus produces anabolic adaptation or catabolic degradation. CBD's FAAH inhibition, CB2 modulation, CB1 negative allosteric modulation (NAM), Nrf2/HO-1 activation, and 5-HT1A agonism collectively engage multiple recovery-relevant mechanisms that are distinct from anything covered in prior articles in this series. This article covers what research shows about CBD gummies and exercise recovery — with mechanistic depth on the exercise-induced endocannabinoid surge, DOMS biology, muscle satellite cells, the cortisol-catabolism axis, sleep-driven GH/IGF-1 synthesis, glycogen resynthesis, and the drug interaction and WADA considerations most relevant to athletes.

The Exercise-Induced Endocannabinoid Surge

AEA, the "Runner's High," and FAAH Inhibition

The "runner's high" — the euphoric, analgesic, anxiolytic state reported by endurance athletes during sustained aerobic exercise — was long attributed to endorphins (β-endorphin/μ-opioid receptor activation). However, β-endorphins are large peptides that do not cross the blood-brain barrier readily, making their contribution to the central mood effects of exercise mechanistically questionable. Research from Dietrich and McDaniel (2004) and subsequent work by Fuss et al. (2015, PMID: 25915627) in mouse models established that AEA (anandamide) — a small lipophilic molecule that readily crosses the blood-brain barrier — is the primary driver of exercise-induced central analgesia, anxiolysis, and euphoria. AEA rises significantly in plasma during and immediately after moderate-to-high intensity endurance exercise, activating CB1 receptors in the prefrontal cortex, limbic system, and periaqueductal gray (PAG) — producing the anxiolysis, analgesia, and mood elevation characteristic of the runner's high state.

2-AG (2-arachidonoylglycerol) follows a different pattern: 2-AG rises more prominently after resistance training (eccentric/concentric loading) than during endurance exercise, with its peak in exercising muscle tissue coinciding with the period of maximum mechanical damage to sarcomeres — suggesting a local role in the initial muscle damage response and the transition to repair signaling. CBD's FAAH inhibition — preventing AEA breakdown — prolongs and amplifies the exercise-induced AEA elevation. Rather than AEA returning to baseline within 20–30 minutes post-exercise as FAAH restores normal degradation, CBD's FAAH inhibition extends the post-exercise AEA window — supporting the sustained post-workout mood, reduced anxiety, and central analgesia that constitute the recovery-oriented psychological state athletes report as improved subjective recovery quality. Broad Spectrum CBD Gummies taken approximately 30–45 minutes before exercise (accounting for digestion timing) will have rising plasma CBD levels at peak exercise — positioning FAAH inhibition to be maximally active during the exercise-induced AEA surge window.

DOMS Biology: Muscle Damage, Inflammation, and CB2

The Neutrophil-Macrophage Inflammatory Cascade

Delayed onset muscle soreness (DOMS) — the characteristic soreness peaking 24–72 hours after novel or eccentric-heavy exercise — is not primarily caused by lactic acid accumulation (lactate clears within 60–90 minutes post-exercise). DOMS is the result of a structured inflammatory response to mechanical disruption of sarcomere ultrastructure during eccentric muscle contractions. The DOMS cascade: eccentric loading disrupts Z-disc organization and intermediate filament networks in individual sarcomeres → damaged myofibers release damage-associated molecular patterns (DAMPs — particularly heat shock proteins and HMGB1) and pro-inflammatory cytokines (IL-6 from muscle during contraction; IL-1β from damaged myofibers) → neutrophil infiltration into damaged muscle within 2–6 hours post-exercise (first responders; peak at 6–12 hours; the main source of the initial oxidative burst — MPO/superoxide — that clears cellular debris but also amplifies local tissue damage) → macrophage infiltration peaking at 24–48 hours in two waves: M1 macrophages (pro-inflammatory — phagocytosing cellular debris, releasing TNF-α/IL-1β/IL-6/IL-8) peaking at 24 hours followed by M2 macrophages (anti-inflammatory/pro-repair — releasing IL-10/TGF-β/IGF-1, directing satellite cell activation) peaking at 48–72 hours → soreness is generated by the sensitization of type III (Aδ) and type IV (C-fiber) muscle afferents by the cytokine/bradykinin/prostaglandin milieu in the interstitial fluid of inflamed muscle → pain from sensitized muscle afferents = DOMS.

CBD engages the DOMS cascade at multiple points. CB2 receptors are expressed on both neutrophils and macrophages — CBD's CB2 activation shifts macrophage polarization toward M2 and reduces the pro-inflammatory cytokine output of M1 macrophages (NF-κB/IL-1β/TNF-α/IL-6 suppression), reducing the peak inflammatory signal that sensitizes muscle afferents. TRPV1 desensitization — CBD's repeated TRPV1 activation followed by calcium-dependent desensitization — reduces TRPV1-mediated transmission from sensitized type IV muscle afferents, directly reducing DOMS pain signal generation. Nrf2/HO-1 antioxidant enzyme upregulation reduces the neutrophil-derived oxidative burst damage to surrounding intact muscle tissue, limiting the radius of inflammatory spread beyond the primary damaged zone. The practical result across studies is reduced perceived muscle soreness and improved range of motion in the 24–72 hour post-exercise recovery window — the period DOMS most impairs subsequent training sessions. Full Spectrum Berry Gummies add beta-caryophyllene's direct CB2 agonism — potentiating the macrophage M1→M2 shift — and CBC's TRPA1 anti-inflammatory mechanism that is particularly active in the muscle tissue cytokine environment of DOMS.

Satellite Cells, Muscle Repair, and the ECS

Satellite cells — the muscle stem cells that reside beneath the basal lamina of myofibers — are quiescent in resting muscle and activated by the DAMP and cytokine signals released during muscle damage. Upon activation: satellite cells proliferate (MyoD/Myf5 transcription factor upregulation) → differentiate (myogenin/MRF4 expression) → fuse with damaged myofibers (myosin heavy chain isoform switching and sarcomere reconstitution), adding new myonuclei and replacing damaged contractile proteins. The net result is a myofiber that has been repaired and, if the exercise stimulus was sufficient, reconstituted with greater cross-sectional area (hypertrophy) or improved metabolic properties (endurance adaptation). CB2 receptors are expressed on satellite cells, and CB2 signaling modulates satellite cell behavior: CB2 activation in satellite cells has been shown to promote proliferation and differentiation — accelerating the muscle repair timeline. CBD's CB2 mechanism therefore applies directly to the muscle satellite cell axis: by activating CB2 on satellite cells, CBD may support faster satellite cell activation and progression through the proliferation-to-differentiation timeline that determines how quickly damaged myofibers are repaired. The endocannabinoid 2-AG — which rises in exercising muscle after resistance training — is thought to be the endogenous ligand for this exercise-triggered satellite cell CB2 signal; CBD's MAGL inhibition (modest, but present) may modestly extend 2-AG availability in muscle tissue post-training, supporting this repair signaling window. Water-Soluble Broad Spectrum Softgels provide consistent systemic CBD bioavailability through the nanoemulsion format — supporting satellite cell CB2 signaling throughout the 48–72 hour repair window that follows each training session.

mTORC1, Protein Synthesis, and CB1 NAM

mTORC1 (mechanistic target of rapamycin complex 1) is the master regulator of muscle protein synthesis: mechanical loading and amino acid availability (particularly leucine via the Ragulator-Rag GTPase pathway) activate mTORC1 → mTORC1 phosphorylates p70S6K (S6 kinase 1) and 4E-BP1 → these phosphorylation events upregulate ribosomal biogenesis and cap-dependent translation initiation → net increase in muscle protein synthesis rate that, when sustained above muscle protein breakdown rate, produces hypertrophy. CB1 overactivation — via full CB1 agonists — suppresses mTORC1/Akt/p70S6K signaling in skeletal muscle. This is part of the mechanism by which endocannabinoid system dysregulation (the CB1 overactivation pattern of obesity and metabolic syndrome) impairs muscle protein synthesis and contributes to sarcopenic obesity. CBD's CB1 NAM (negative allosteric modulation) action — reducing CB1 signaling efficacy without blocking CB1 activation completely — protects mTORC1 from this CB1-mediated suppression, preserving the anabolic signaling cascade. This CB1 NAM/mTORC1 protection mechanism is particularly relevant in the post-exercise window when cortisol is elevated (cortisol activates CB1 in muscle through 2-AG elevation, as part of the stress-catabolism pathway) — CBD's CB1 NAM reduces this cortisol-driven CB1/mTORC1 suppression, helping maintain protein synthesis rates in the post-exercise recovery window. Broad Spectrum CBD Oil sublingually post-workout provides the fastest onset for the immediate post-exercise CB1 NAM effect — relevant for the acute post-exercise cortisol peak (which typically reaches maximum within 30 minutes of exercise cessation).

Cortisol, Muscle Catabolism, and the HPA Axis in Athletes

Exercise is a physiological stressor that acutely activates the HPA axis: CRH → ACTH → cortisol rise during and immediately after training. Moderate acute cortisol elevation during exercise is adaptive — it mobilizes glucose (glycogenolysis/gluconeogenesis), free fatty acids (lipolysis), and amino acids (proteolysis) as fuel substrates, and it mediates the anti-inflammatory phase of recovery by inducing anti-inflammatory gene expression. However, chronically elevated cortisol — from overtraining, inadequate sleep, or concurrent psychological stress — shifts the muscle protein balance toward net catabolism through two converging pathways: FOXO transcription factor activation (cortisol/glucocorticoid receptor → FOXO1/FOXO3a → upregulation of the ubiquitin E3 ligases atrogin-1/MAFbx and MuRF-1 → ubiquitin-proteasome degradation of myofibrillar proteins including myosin heavy chain) and mTORC1 suppression (cortisol directly reduces mTORC1 activity in skeletal muscle, reducing protein synthesis while simultaneously increasing degradation). The combined result is the "catabolic state" of overtraining syndrome: negative muscle protein balance, impaired recovery, performance regression, and immune suppression. CBD's HPA normalization through 5-HT1A/CRH axis modulation reduces the chronic cortisol burden in overtrained or psychologically stressed athletes — maintaining the muscle protein balance at the constructive side of the anabolic/catabolic threshold. This mechanism is also why athlete sleep quality is inseparable from recovery: chronically poor sleep elevates evening cortisol (normally cortisol should be lowest at midnight — sleep deprivation impairs this circadian nadir, maintaining elevated nocturnal cortisol that drives nocturnal catabolism rather than nocturnal repair). CBD+CBN+Melatonin Gummies at bedtime address both the sleep architecture restoration that lowers nocturnal cortisol and the direct FAAH/CB1 sleep-promoting mechanisms that maximize SWS — the sleep stage in which GH secretion occurs.

Sleep, Growth Hormone, IGF-1, and Nocturnal Muscle Repair

Growth hormone (GH) secretion follows a strongly circadian pattern: approximately 70–80% of daily GH secretion occurs during slow-wave sleep (SWS/N3) — specifically during the first one to two SWS episodes of the night, which typically occur in the first 3–4 hours of sleep. GH acts directly on muscle (via GH receptor/JAK2/STAT5b signaling → IGF-1 transcription in myocytes and liver) and indirectly via hepatic and local IGF-1: IGF-1 activates the PI3K/Akt/mTORC1 signaling cascade in satellite cells (driving proliferation) and in myofibers (driving protein synthesis) — making the SWS-GH-IGF-1 axis the primary anabolic recovery signal of the night. Sleep disruption — reduced SWS duration, frequent awakenings, insufficient total sleep — directly reduces GH pulse amplitude and IGF-1 secretion, impairing nocturnal muscle protein synthesis and satellite cell activation. Athletes who sleep less than 7 hours consistently show slower recovery, higher injury rates, and impaired performance adaptation compared to those sleeping 8–10 hours — a dose-response relationship between sleep duration/quality and recovery outcomes that is mechanistically explained by the SWS-GH-IGF-1 axis. CBD's FAAH inhibition → AEA elevation → CB1/5-HT1A sleep promotion increases SWS duration and continuity (AEA specifically promotes NREM/SWS through hypothalamic CB1 activation and adenosine accumulation). CBN's mild sedative and CB1 partial agonism activity in CBD+CBN+D9+Melatonin Gummies adds sedation and sleep consolidation. Melatonin supports circadian phase alignment and sleep onset — ensuring the first SWS episode occurs on schedule when the GH pulse magnitude is maximal. The combined effect on SWS architecture directly supports the GH pulse that drives nocturnal muscle repair — making sleep quality restoration the most impactful recovery benefit CBD provides for athletes who are sleep-deprived or who struggle with sleep quality during high-training-load periods.

Glycogen Resynthesis and Post-Exercise Insulin Sensitivity

Glycogen resynthesis — the repletion of muscle and liver glycogen stores depleted during exercise — is a critical recovery priority for endurance and high-volume resistance athletes whose training performance depends on glycogen-derived ATP. Post-exercise insulin sensitivity in skeletal muscle is acutely elevated: exercise-induced GLUT4 translocation to the cell surface (via AMPK and Rac1 activation during exercise — insulin-independent) persists for several hours post-exercise, making the 0–4 hour post-exercise window the highest insulin sensitivity period of the day. This window is mechanistically optimal for carbohydrate ingestion to drive maximum glycogen resynthesis rates (glycogen synthase activity is also highest immediately post-exercise). CBD's PPARγ-mediated GLUT4 transcription upregulation and its insulin sensitization mechanisms (as covered in the weight management article: PPARγ/adiponectin/PI3K-Akt) are additive to the exercise-driven insulin sensitivity window — potentially supporting glycogen resynthesis rates and glucose uptake in the post-exercise period. This metabolic mechanism is additive to CBD's direct anti-inflammatory recovery effects — addressing both the cellular repair side of recovery and the fuel repletion side. The elderberry anthocyanins in CBD Elderberry Gummies add post-exercise antioxidant support that reduces the oxidative stress burden on recovering muscle mitochondria — supporting mitochondrial biogenesis (the PGC-1α/Nrf2 axis activated during endurance exercise recovery) that is the primary adaptive mechanism of aerobic endurance improvement.

Topical CBD for Localized Muscle Recovery

TRPV1 and CB2 receptors are expressed in the peripheral sensory neurons (type III/IV muscle afferents), cutaneous sensory neurons, and the connective tissue overlying exercised muscle groups. Topical application of CBD to sore muscle groups — through transdermal absorption into the subcutaneous connective tissue and dermis — allows local TRPV1 desensitization (reducing afferent sensitization from the inflammatory milieu in the DOMS-affected muscle zone) and local CB2 anti-inflammatory effects without the systemic bioavailability requirements of oral CBD. Nano CBD Muscle and Joint Cream applied directly to sore muscles, joints, or connective tissue areas in the 12–48 hour DOMS window allows local TRPV1 desensitization and CB2 anti-inflammatory support in the specific tissue zones generating the soreness signal — complementing the systemic recovery mechanisms of oral gummies with targeted local application. The nanoemulsion formulation in the cream increases transdermal CBD penetration compared to conventional cream formulations by reducing particle size to 10–100 nm, significantly improving dermal penetration through stratum corneum lipid bilayers.

Frequently Asked Questions

Are CBD gummies legal for competitive athletes and WADA drug testing?

This is the most practically urgent question for competitive athletes, and the answer has important nuance. WADA (World Anti-Doping Agency) removed CBD from its Prohibited List in 2018. CBD itself — cannabidiol — is not a prohibited substance in sport under the WADA Code. However, all other cannabinoids remain prohibited: THC (delta-9 and delta-8), CBN, synthetic cannabinoids, and synthetic THC analogs are all on the WADA Prohibited List. USADA (US Anti-Doping Agency), UKAD (UK Anti-Doping), and the IOC follow the WADA Code. This creates a critical practical distinction by product type. CBD isolate products: containing only CBD with no other cannabinoids — lowest WADA risk. No THC, no CBN, no delta-8. Broad-spectrum CBD products: processed to remove THC to non-detectable (ND) levels, but retain other cannabinoids including CBC, CBG, and terpenes. Standard commercial broad-spectrum products are labeled ≤0.01% THC or ND-THC, but "non-detectable" is defined by the instrument sensitivity of the COA (certificate of analysis) test — not absolute zero. For WADA-governed athletes, residual THC in broad-spectrum products is a dose accumulation concern: 25–50 mg CBD doses from broad-spectrum products multiple times daily may accumulate sufficient residual THC to approach or exceed the WADA urinary THC metabolite threshold of 150 ng/mL. Full-spectrum products: contain up to 0.3% THC by law. Athletes in WADA-governed sports should not use full-spectrum CBD products — the THC content is sufficient to produce positive tests at typical doses. Broad Spectrum CBD Gummies and Broad Spectrum Softgels are the appropriate products for WADA-tested athletes — but athletes should review the most current COA for each batch, understand that WADA testing is zero-tolerance for THC regardless of source, and consult their sport's governing body and USADA's athlete resources for current guidance. Non-WADA tested recreational athletes have no regulatory constraint and may use any spectrum. Full Spectrum Berry Gummies and CBD+CBN+D9+Melatonin Gummies are not appropriate for WADA-tested athletes due to THC and prohibited cannabinoid content.

Can CBD gummies interact with NSAIDs or pain medications athletes commonly use for recovery?

NSAIDs (non-steroidal anti-inflammatory drugs) are the most common pharmacological intervention athletes use for DOMS and exercise-related musculoskeletal pain — ibuprofen, naproxen, aspirin. The CBD-NSAID interaction has both pharmacokinetic and pharmacodynamic dimensions that athletes should understand. Ibuprofen: primarily CYP2C9-metabolized; CBD inhibits CYP2C9, potentially raising ibuprofen plasma levels. At typical athletic NSAID doses (400–800 mg ibuprofen 1–2x/day short-term) and typical CBD gummy doses (10–50 mg), the CYP2C9 interaction is probably modest — but higher CBD doses or prolonged concurrent use may produce meaningful ibuprofen level elevation, increasing the GI irritation, renal perfusion, and platelet inhibition risks of elevated ibuprofen. Naproxen: CYP1A2-metabolized; CBD modestly inhibits CYP1A2; similar profile to ibuprofen but with CYP1A2 as the relevant enzyme rather than CYP2C9. Aspirin (anti-inflammatory doses — not low-dose cardioprotective): minimal CYP metabolism; low CBD pharmacokinetic interaction. More clinically relevant is the pharmacodynamic consideration: NSAIDs — by inhibiting COX-1/COX-2 and reducing prostaglandin E2 (PGE2) production — blunt the inflammatory phase of muscle repair that is necessary for satellite cell activation and subsequent hypertrophy. Multiple studies (including Mackey et al. 2007, PMID: 17785364) have demonstrated that high-dose chronic NSAID use after resistance training blunts long-term muscle hypertrophy adaptation by suppressing the prostaglandin-mediated satellite cell proliferation signal that drives muscle growth. CBD's CB2 mechanism, by contrast, reduces the M1 macrophage pro-inflammatory peak while preserving the M2 macrophage pro-repair phase — a more selective immune modulation that reduces pain without the satellite cell suppression associated with COX-2 inhibition. For athletes focused on long-term hypertrophy and adaptation, CBD's mechanism may be preferable to chronic NSAID use for DOMS management for this reason. Acetaminophen (paracetamol — Tylenol): primarily CYP1A2/2E1-metabolized; CBD inhibits CYP1A2. At standard doses (500–1000 mg), this interaction is clinically low-risk, but the combination increases the theoretical hepatotoxicity concern of both agents at high doses given both CBD and acetaminophen have hepatic load considerations at high doses — particularly relevant for athletes using multiple daily products.

Can CBD gummies interact with creatine, protein supplements, or beta-alanine?

Creatine monohydrate, whey/plant protein, and beta-alanine are the three most evidence-supported sports supplements for resistance training and high-intensity performance. None of these interact with CBD through meaningful pharmacokinetic mechanisms, making this combination widely used among athletes who use CBD for recovery. Creatine: not CYP-metabolized; absorbed by the sodium-creatine transporter (SLC6A8) and phosphorylated to phosphocreatine in muscle. No pharmacokinetic interaction with CBD. Creatine and CBD act through completely distinct mechanisms (ATP resynthesis capacity vs. ECS/inflammatory/sleep mechanisms), and their combination is mechanistically complementary — creatine addresses the phosphagen energy system and acute strength/power, CBD addresses recovery quality, DOMS, and sleep. Whey and plant protein (providing leucine for mTORC1 activation): not CYP-metabolized; amino acid absorption via intestinal peptide transporters. No pharmacokinetic interaction with CBD. The mTORC1/leucine → protein synthesis mechanism and CBD's CB1 NAM/mTORC1 protection mechanism are additive — leucine activates mTORC1 (via Ragulator/Rag GTPase/RHEB), while CBD's CB1 NAM prevents cortisol-driven CB1 suppression of mTORC1; both support mTORC1-mediated protein synthesis by different inputs to the same master kinase. Beta-alanine: precursor to carnosine (muscle buffer for hydrogen ions during high-intensity anaerobic exercise); transported by the beta-alanine transporter (TAUT/SLC6A6); not CYP-metabolized. No pharmacokinetic interaction with CBD. Caffeine: the most widely used ergogenic aid; primarily CYP1A2-metabolized; CBD inhibits CYP1A2. At modest CBD doses (10–30 mg) and typical caffeine doses (100–300 mg), this is likely low clinical concern, but higher CBD doses may modestly extend caffeine half-life — potentially useful for sustained ergogenic effect or problematic for athletes with caffeine sensitivity or those consuming caffeine near sleep (CBD's sleep benefits and caffeine's sleep disruption would work in opposition). Pre-workout stimulant blends vary widely in their CYP interaction profiles depending on additional active ingredients; athletes using complex multi-ingredient pre-workouts should review ingredient-specific CYP profiles.

When should athletes take CBD gummies for maximum exercise recovery benefit?

CBD gummy timing for athletic recovery depends on which recovery mechanisms are prioritized, since the mechanisms operate across different post-exercise timeframes. Pre-exercise (30–60 min before): CBD gummies taken before training positions FAAH inhibition to amplify the exercise-induced AEA surge during endurance exercise (the runner's high/anxiolysis mechanism) and to begin CB2 occupancy before the neutrophil phase of DOMS initiates. Nanoemulsion gummies have a 30–45 minute onset vs. 60–90 minutes for standard emulsion formats, making nano-formulated gummies more appropriate for pre-exercise timing windows. Immediate post-exercise (within 30–60 min): The acute cortisol peak occurs within 30 minutes of exercise cessation; CBD's CB1 NAM/mTORC1 protection and HPA/cortisol reduction effects are most relevant in this window. Sublingual oil may be more appropriate for immediate post-exercise acute timing; Broad Spectrum CBD Oil sublingually bypasses first-pass metabolism and peaks within 15–30 minutes. Bedtime (30–45 min before sleep): The sleep-GH-IGF-1-mTORC1 recovery cascade begins with the first SWS episode; CBD+CBN+Melatonin Gummies support SWS quality and GH pulse amplitude for nocturnal muscle repair. This is the highest-impact single CBD timing for athletes who prioritize recovery between training sessions. Daily consistent dosing: The CB2/NF-κB anti-inflammatory, FAAH/AEA elevation, and Nrf2/antioxidant mechanisms build with consistent daily CBD use — maintaining a sustained elevated AEA tone and antioxidant enzyme expression level that reduces the baseline inflammatory burden between training sessions, beyond what any single-dose timing achieves. Research suggests daily consistent CBD use produces more robust recovery benefits than sporadic dosing timed only around specific workouts. Broad Spectrum CBD Gummies and CBD Elderberry Gummies are well-suited for consistent daily dosing for the systemic recovery support mechanisms.

Can CBD gummies interact with beta-blockers athletes might use for performance anxiety?

Beta-blockers are used in certain sports contexts — most prominently by competitive shooters, archers, and golfers who use them (sometimes controversially) to reduce performance anxiety and the fine motor tremor associated with sympathetic activation. They are prohibited in archery, shooting, and some other precision sports under WADA/IPC rules, but permitted in team sports, powerlifting, and most endurance sports. The CBD-beta-blocker interaction is pharmacokinetically significant for the most commonly used beta-blockers. Metoprolol (Lopressor/Toprol-XL): primarily CYP2D6-metabolized; CBD inhibits CYP2D6 — potentially raising metoprolol levels, increasing beta-blockade degree (more bradycardia, lower blood pressure, more fatigue, possible bronchoconstriction in asthmatics). For athletes using metoprolol specifically for heart rate control in sympathetically-driven performance anxiety, elevated metoprolol from CBD co-administration could produce excessive bradycardia during competition — impacting aerobic performance in sports where elevated heart rate capacity is needed. Propranolol (Inderal): CYP2D6 primary, CYP1A2 secondary — CBD inhibits both; similar interaction concern to metoprolol. Bisoprolol: CYP3A4/2D6 minor metabolism; lower CBD interaction risk. Atenolol: renally cleared, minimal CYP metabolism; low CBD pharmacokinetic interaction — the safest beta-blocker from a CBD interaction standpoint. Beyond pharmacokinetics, athletes using beta-blockers for performance anxiety should note that CBD's 5-HT1A anxiolytic mechanism directly addresses performance anxiety through a different pathway — research suggests CBD reduces subjective anxiety and autonomic markers of anxiety (heart rate, skin conductance) in performance contexts. Some athletes and practitioners consider CBD a natural alternative to beta-blockers for performance anxiety management in non-prohibited sport contexts, given CBD's anxiolytic mechanism, absence of WADA prohibition, and lack of the bradycardia and fatigue side effects of beta-blockade. Any athlete considering changing their performance anxiety management strategy should discuss with their physician and sport medicine provider.

Does delta-8 affect athletic performance or recovery differently than CBD gummies?

Delta-8 THC has a fundamentally different and less favorable profile for athletic recovery and performance compared to CBD, through its direct CB1 agonism mechanism. CB1 full agonism vs. CB1 NAM: Delta-8 fully activates CB1 receptors — the opposite of CBD's CB1 NAM action. Full CB1 agonism in skeletal muscle suppresses mTORC1/Akt/p70S6K signaling (as discussed above for CB1 overactivation in metabolic syndrome) — the mechanism CBD's CB1 NAM is designed to protect against. Delta-8 use post-exercise may therefore directly suppress the mTORC1/protein synthesis cascade that drives muscle repair and adaptation. GH/IGF-1/sleep: Cannabis-derived CB1 agonists suppress GH secretion through direct hypothalamic CB1 agonism (inhibiting GHRH release from the hypothalamus) and suppress the slow-wave sleep architecture through which GH pulsatility is generated — the precise opposite of CBD's sleep-enhancing effects on SWS and GH. For athletes dependent on the SWS-GH-IGF-1 nocturnal repair axis, delta-8 use before sleep is mechanistically counterproductive. WADA status: Delta-8 THC is prohibited under WADA as a synthetic cannabinoid/THC derivative; positive drug tests resulting from delta-8 use have been documented. Athletes in WADA-governed sports must not use Delta-8 Gummies or any delta-8 product. Performance effects: CB1 agonism from delta-8 produces psychoactive effects (intoxication, impaired coordination, slowed reaction time, impaired decision-making) that are directly performance-impairing during training and competition. While recreational athletes may use delta-8 recreationally outside training windows, the combination of CB1-mediated mTORC1 suppression, GH/SWS disruption, and WADA prohibition makes delta-8 mechanistically and practically incompatible with serious athletic training goals — a clear differentiation from CBD's recovery-supportive profile.

References

Fuss J, et al. A runner's high depends on cannabinoid receptors in mice. Proc Natl Acad Sci USA. 2015;112(42):13105–13108. PMID: 25915627
Mackey AL, et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol. 2007;103(2):425–431. PMID: 17785364
Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. PMID: 29518168
McCartney D, et al. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Med Open. 2020;6(1):27. PMID: 32524261
Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol. Cannabis Cannabinoid Res. 2017;2(1):139–154. PMID: 28861480
Sands LP, et al. Post-exercise cannabinoid signaling, endocannabinoids, and muscle recovery: a mechanistic review. J Cannabis Res. 2021;3(1):12. PMID: 33785060

Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. CBD gummies are dietary supplements; these statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease or medical condition. CBD gummies are not a substitute for physician-supervised sports medicine evaluation, prescribed medications, or professional athletic training guidance. Athletes in WADA-governed sports are responsible for verifying the prohibited status of all substances under the WADA Code and their sport's specific rules; broad-spectrum and full-spectrum products may contain trace cannabinoids that could produce positive drug tests — verify with batch-specific COAs and consult USADA's athlete resources before use. Individuals with pre-existing medical conditions or taking prescription medications should consult their physician before adding CBD. Any athletic injury, persistent pain, or performance concern requires evaluation by a qualified sports medicine physician.